Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1 resulting in tumor proliferation in CRC
BRAFV600E mutation accounts for up to 90% of all BRAF mutations in human colorectal cancer (CRC), and constitutively activates MEK-MAPK pathway. It is recognized that the monoclonal antibody to epidermal growth factor receptor alone is not effective for CRC with BRAFV600E mutation. Therefore, there is increasing interest in the identification of possible therapeutic targets in the downstream of BRAF mutations in CRC. To address this, […]